PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
64.33 USD
+0.23 (+0.36%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
In the past year PBH had a positive cash flow from operations.
Of the past 5 years PBH 4 years were profitable.
In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.21%, PBH belongs to the top of the industry, outperforming 90.31% of the companies in the same industry.
PBH has a better Return On Equity (11.48%) than 87.24% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.95%, PBH belongs to the top of the industry, outperforming 84.69% of the companies in the same industry.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 19.02%, PBH belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
PBH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.15%, PBH belongs to the top of the industry, outperforming 94.90% of the companies in the same industry.
PBH's Operating Margin has been stable in the last couple of years.
The Gross Margin of PBH (56.13%) is better than 64.80% of its industry peers.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PBH has less shares outstanding
Compared to 5 years ago, PBH has less shares outstanding
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.65 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.65. This is in the better half of the industry: PBH outperforms 69.90% of its industry peers.
PBH has a debt to FCF ratio of 3.79. This is a good value and a sign of high solvency as PBH would need 3.79 years to pay back of all of its debts.
PBH's Debt to FCF ratio of 3.79 is amongst the best of the industry. PBH outperforms 88.27% of its industry peers.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 62.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.65 |
ROIC/WACC0.86
WACC9.28%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
The Current ratio of PBH (4.38) is better than 66.84% of its industry peers.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Quick ratio of 2.99. This is comparable to the rest of the industry: PBH outperforms 58.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.21% over the past year.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 0.63% in the last year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 3.32% on average per year.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.05, the valuation of PBH can be described as correct.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.24% of the companies in the same industry.
PBH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.41.
Based on the Price/Forward Earnings ratio of 13.32, the valuation of PBH can be described as correct.
83.67% of the companies in the same industry are more expensive than PBH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, PBH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.05 | ||
| Fwd PE | 13.32 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 88.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 89.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.82 | ||
| EV/EBITDA | 10.64 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)15.16
PEG (5Y)1.58
EPS Next 2Y3.24%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PBH (9/19/2025, 9:50:06 AM)
64.33
+0.23 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.49%
Inst Owner Change-0.47%
Ins Owners1.26%
Ins Owner Change5.74%
Market Cap3.17B
Analysts78
Price Target85.27 (32.55%)
Short Float %2.92%
Short Ratio2.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-6.9%
PT rev (3m)-7.93%
EPS NQ rev (1m)-9.34%
EPS NQ rev (3m)-18.97%
EPS NY rev (1m)-5.1%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)-2.32%
Revenue NQ rev (3m)-11.47%
Revenue NY rev (1m)-3.7%
Revenue NY rev (3m)-3.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.05 | ||
| Fwd PE | 13.32 | ||
| P/S | 2.83 | ||
| P/FCF | 11.82 | ||
| P/OCF | 11.48 | ||
| P/B | 1.71 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.64 |
EPS(TTM)4.58
EY7.12%
EPS(NY)4.83
Fwd EY7.51%
FCF(TTM)5.44
FCFY8.46%
OCF(TTM)5.6
OCFY8.71%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)15.16
PEG (5Y)1.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.65 |
F-Score8
WACC9.28%
ROIC/WACC0.86
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.24%
EBIT Next 3Y3.43%
EBIT Next 5Y2.94%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%